Summary: The ECE2 gene has been linked to an increased risk of developing late-onset Alzheimer’s disease.
Source: University of British Columbia
Researchers from the University of British Columbia (UBC) and the Central South University (CSU) in China have for the first time identified a gene that increases the risk of Alzheimer’s disease.
In the study, published recently in the journal JCI Insight, the researchers found two mutations in the gene endothelin-converting enzyme 2 (ECE2) which impaired its ability to break down amyloid beta protein. These mutations were present significantly more often in people with Alzheimer’s than in controls–suggesting that the genetic variants in ECE2 could be causing, or at least contributing to, Alzheimer’s symptoms.
“Since amyloid beta protein is unique to Alzheimer’s disease, the majority of drug development was targeted here,” says Dr. Weihong Song, who is the Canada Research Chair in Alzheimer’s disease, Jack Brown and Family Professor, and director of UBC’s Townsend Family Laboratories. “If we can prevent amyloid beta protein build-up or at least find a way to get rid of some of it, we could prevent and treat the disease.”
Song’s laboratory at UBC collaborated with Dr. Lu Shen’s team at Xiangya Hospital at CSU for the study. The study’s lead author is Dr. Xinxin Lio who completed a joint PhD at UBC and CSU.
The scientists looked at 741 people with late-onset Alzheimer’s and compared them to controls. Unlike early-onset which affects people as young as 30, late-onset Alzheimer’s is the most common form of this disease, generally affecting individuals after the age of 65.
Song’s lab focuses its efforts on looking at the role amyloid beta protein plays in Alzheimer’s. It’s well established that increased production (or reduced degradation) of amyloid beta protein results in the formation of neuritic plaques in the brain, which is a hallmark of Alzheimer’s disease neuropathology.
The team injected the mutated forms of the ECE2 gene into mice. They found mice with the mutation had increased levels of amyloid beta protein and plaque formation, and also exhibited some signs of Alzheimer’s such as memory loss. When they expressed the wildtype form of the gene in the mice (i.e. the non-mutated form), amyloid beta protein levels decreased and the mice recovered some of their learning and memory deficits.
“These findings mean that ECE2 is a risk gene for people to develop Alzheimer’s later in life,” says Song.
“Moving forward, we can try to target this gene and increase its expression as a way to treat Alzheimer’s.”
The researchers are now screening further for genetic mutations in a larger dataset as a way to validate these findings and to search for other variants in the ECE2 gene that could be contributing to Alzheimer’s symptoms.
Source:
University of British Columbia
Media Contacts:
Vanessa Hrvatin – University of British Columbia
Image Source:
The image is in the public domain.
Original Research: Open access
“Identification of Alzheimer’s disease–associated rare coding variants in the ECE2 gene”. Xinxin Liao, Fang Cai, Zhanfang Sun, Yun Zhang, Juelu Wang, Bin Jiao, Jifeng Guo, Jinchen Li, Xixi Liu, Lina Guo, Yafang Zhou, Junling Wang, Xinxiang Yan, Hong Jiang, Kun Xia, Jiada Li, Beisha Tang, Lu Shen, Weihong Song.
JCI Insight doi:10.1172/jci.insight.135119.
Abstract
Identification of Alzheimer’s disease–associated rare coding variants in the ECE2 gene
Accumulation of amyloid β protein (Aβ) due to increased generation and/or impaired degradation plays an important role in Alzheimer’s disease (AD) pathogenesis. In this report, we describe the identification of rare coding mutations in the endothelin-converting enzyme 2 (ECE2) gene in 1 late-onset AD family, and additional case-control cohort analysis indicates ECE2 variants associated with the risk of developing AD. The 2 mutations (R186C and F751S) located in the peptidase domain in the ECE2 protein were found to severely impair the enzymatic activity of ECE2 in Aβ degradation. We further evaluated the effect of the R186C mutation in mutant APP–knockin mice. Overexpression of wild-type ECE2 in the hippocampus reduced amyloid load and plaque formation, and improved learning and memory deficits in the AD model mice. However, the effect was abolished by the R186C mutation in ECE2. Taken together, the results demonstrated that ECE2 peptidase mutations contribute to AD pathogenesis by impairing Aβ degradation, and overexpression of ECE2 alleviates AD phenotypes. This study indicates that ECE2 is a risk gene for AD development and pharmacological activation of ECE2 could be a promising strategy for AD treatment.
